Close Menu

NEW YORK – Chinese cancer genomic profiling firm Genetron Health said on Tuesday that its Detection Kit for Novel Coronavirus (SARS-CoV-2) RNA (PCR-Fluorescence Probing) has received the CE mark.

The company also said that three of its clinical laboratories have passed a COVID-19 external quality assessment by China's National Center for Clinical Laboratories (NCCL).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.

A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.

NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.

In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.